In a randomised platform trial, 586 adults got 1,049 extra doses of nine licensed COVID-19 vaccines: local reactions followed 75% and systemic reactions 76% of doses, and severe events were rare. Nvx seemed less reactogenic than mRNA vaccines (not powered to compare).
RCTn = 586
C et al. The platform trial in COVID-19 priming and BOOsting (PICOBOO): The reactogenicity of nine licensed COVID-19 vaccines delivered in immunocompetent adults